ClinVar Miner

Submissions for variant NM_001298.3(CNGA3):c.1641C>A (p.Phe547Leu)

dbSNP: rs104893617
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Centre for Mendelian Genomics, University Medical Centre Ljubljana RCV000415000 SCV000492976 likely pathogenic Monochromacy 2014-07-21 criteria provided, single submitter clinical testing
Invitae RCV001055558 SCV001219956 pathogenic not provided 2024-01-22 criteria provided, single submitter clinical testing This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 547 of the CNGA3 protein (p.Phe547Leu). This variant is present in population databases (rs104893617, gnomAD 0.07%). This missense change has been observed in individual(s) with achromatopsia (PMID: 9662398, 11536077, 14757870, 23972307, 30682209). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 9478). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CNGA3 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CNGA3 function (PMID: 17693388). For these reasons, this variant has been classified as Pathogenic.
Blueprint Genetics RCV001074686 SCV001240279 pathogenic Retinal dystrophy 2019-03-23 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV001055558 SCV001249389 pathogenic not provided 2022-09-01 criteria provided, single submitter clinical testing CNGA3: PM3:Very Strong, PM2, PP3, PP4, PS3:Supporting
Centre for Mendelian Genomics, University Medical Centre Ljubljana RCV000010086 SCV001369955 pathogenic Achromatopsia 2 2018-11-12 criteria provided, single submitter clinical testing This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM3,PP3,PP4. This variant was detected in homozygous state.
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV001055558 SCV001762265 pathogenic not provided 2021-06-17 criteria provided, single submitter clinical testing
GeneDx RCV001055558 SCV001768121 pathogenic not provided 2022-12-16 criteria provided, single submitter clinical testing Published functional studies demonstrate loss of electrophysiological activity in the mutant channel compared to wild type (Matveev et al., 2010; Muraki-Oda et al., 2007); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 16961972, 31429209, 32531858, 23972307, 20088482, 9662398, 17693388, 18521937, 25168900, 27040408, 19592100, 11536077, 14757870, 24148654, 16319819, 30682209, 30653986, 31456290, 33562422, 31589614, 34426522, 34449556)
Neuberg Centre For Genomic Medicine, NCGM RCV000010086 SCV002073303 pathogenic Achromatopsia 2 criteria provided, single submitter clinical testing The missense variant p.F547L in CNGA3 (NM_001298.3) has been reported previously in homozygous as well as compound heterozygous state in affected indviduals (Fahim AT et al; Georgiou M et al).It is known to affect protein function (Muraki-Oda S et al). It has been submitted to ClinVar as Pathogenic/Likely Pathogenic. It is present in 45 alleles in heterozygous state in the gnomad database (0.1%) as well as it has been observed in homozygous state in one individual. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000010086 SCV004099714 pathogenic Achromatopsia 2 2023-09-01 criteria provided, single submitter clinical testing Variant summary: CNGA3 c.1641C>A (p.Phe547Leu) results in a non-conservative amino acid change located in the cyclic nucleotide-binding domain (IPR000595) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00015 in 251308 control chromosomes in the gnomAD database, including 1 homozygote. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1641C>A has been reported in the literature in numerous homozygous and compound heterozygous individuals affected with Achromatopsia 2 (e.g., Sun_2020). These data indicate that the variant is very likely to be associated with disease. The following publication was ascertained in the context of this evaluation (PMID: 32913385). Seven submitters have reported clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
OMIM RCV000010086 SCV000030307 pathogenic Achromatopsia 2 2001-10-01 no assertion criteria provided literature only
Sharon lab, Hadassah-Hebrew University Medical Center RCV001002970 SCV001161018 pathogenic Achromatopsia 2019-06-23 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.